GP-100 antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
GP-100 antigen
Accession Number
DB14800
Type
Biotech
Groups
Investigational
Description

GP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).

Synonyms
  • GP100 ANTIGEN
Categories
Not Available
UNII
1NU720978F
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentIntraocular Melanoma / Melanoma (Skin)1
1CompletedTreatmentMelanoma (Skin)7
1TerminatedTreatmentIntraocular Melanoma / Melanoma (Skin)1
1, 2CompletedTreatmentMelanoma (Skin)2
1, 2Unknown StatusTreatmentMelanoma (Skin)1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Extraocular Extension Melanoma / Iris Melanoma / Metastatic Intraocular Melanoma / Mucosal Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IIC Melanoma / Stage IIIA Intraocular Melanoma / Stage IIIA Melanoma / Stage IIIB Intraocular Melanoma / Stage IIIB Melanoma / Stage IIIC Intraocular Melanoma / Stage IIIc Melanoma / Stage IV Intraocular Melanoma / Stage IV Melanoma1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Stage IIB Melanoma / Stage IIC Melanoma / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIc Melanoma / Stage IV Melanoma1
2CompletedTreatmentExtraocular Extension Melanoma / Recurrent Intraocular Melanoma1
2CompletedTreatmentIntraocular Melanoma / Melanoma (Skin)3
2CompletedTreatmentMelanoma (Skin)11
2CompletedTreatmentMelanoma (Skin) / Non-Melanomatous Skin Cancer1
2CompletedTreatmentRecurrent Melanoma / Renal Cell Cancer, Recurrent / Stage IV Melanoma / Stage IV Renal Cell Cancer1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2TerminatedTreatmentMelanoma (Skin)1
2TerminatedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2Unknown StatusTreatmentMelanoma (Skin)1
3CompletedTreatmentRecurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
3TerminatedTreatmentIntraocular Melanoma1
Not AvailableCompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:27 / Updated on May 21, 2019 12:29